Encoll Corporation specializes in the development and manufacturing of Type-I collagen-based products, leveraging patented technologies to produce high-purity and charge-modified collagen. Their proprietary Two-step enzyme Treatment Process (TTP) ensures that the collagen is 99% pure, significantly reducing immunogenicity and enhancing bioactivity, which is crucial for various medical applications. This advanced purification method addresses common issues found in traditional collagen products, such as contamination with type-III collagen, which can lead to rejection in human implants. Encoll's collagen products are designed for a wide range of medical fields, including general and plastic surgery, orthopedic surgery, oral surgery, and neurological injuries, as well as applications in drug delivery and biopharmaceutical research.

One of Encoll's flagship products, Helicoll®, is a bioengineered acellular skin substitute that promotes tissue regeneration and wound healing. With over 97% purity, Helicoll® provides a supportive framework for blood vessel regeneration and cell migration, making it an effective solution for managing wounds. The product has been recognized for its clinical effectiveness, receiving an Innovative Technology contract from Vizient, Inc. Encoll's commitment to quality is reflected in their adherence to stringent manufacturing standards set by regulatory organizations such as the FDA and WHO, ensuring that their collagen products meet the highest safety and efficacy benchmarks for biomedical applications.

United States

ENCOLL CORP. is a medical devices company based out of 4576 ENTERPRISE STREET, FREMONT, California, United States.

Encoll

Company Details